About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

As the successor to the Nintendo Switch console, the Nintendo Switch 2 will feature a large library of games that can be played both in handheld mode and from ...

Nintendo sold 1.6 million Switch 2 consoles in June 2025 Nintendo Switch 2 becomes fastest-selling game console in US history Sony's 12-year reign has ended PlayStation 5 remains 2025 's best-selling ...

With the completion of the successful Phase 3 VERITAC-2 trial, in June 2025 Pfizer and Arvinas filed an NDA seeking FDA approval.

VERITAC-2 was the first head-to-head study to compare the efficacy and safety of vepdegestrant with the intramuscular SERD fulvestrant in patients with advanced ER+/HER2- BC after combination CDK4/6 ...

Early diagnosis of type 2 diabetes can help prevent complications. Learn about the tests doctors use to diagnose the condition.